Allergy advocacy group Food Allergy Research and Education says that the U.S. is facing a growing national shortage of EpiPens and other allergic reaction treatments called epinephrine auto-injectors. Individuals with food allergies have found it difficult to fill their prescriptions in as many as 14 states as of late April, the group said. The American Society of Health-System Pharmacists, a professional organization for pharmacists, also said that there was a shortage of Mylan’s EpiPen , with the EpiPen, EpiPen Jr. for children and the authorized generic version “on intermittent back order with regular releases,” earlier this month. A rival product manufactured by Kaleo was still available, the group said. The Food and Drug Administration did not immediately return MarketWatch’s request for comment, but a spokesperson said in late April that it was not aware at that time of any shortage. A FDA spokesperson then called it a “spot shortage” in late April, according to the publication Allergic Living. The advocacy group FARE said it wrote to FDA Commissioner Scott Gottlieb on May 1 about its concerns, and said on Monday that it was calling on the FDA to declare the issue a national shortage. EpiPen shortages have been seen in Canada and the United Kingdom. FARE also questioned whether there was a connection between the supply issues and problems at a Pfizer unit that manufactures the EpiPen, and asked the FDA to push for other allergic reaction treatments from Teva and Adamis Pharmaceuticals Corp. , which got its Symjepi product approved last July, though the product has not been brought to market.